Kaempferol’s potential in targeting IL-17–mediated inflammatory pathways for colorectal cancer treatment
The Journal of Immunology · 2026
DOI: 10.1093/jimmun/vkag176 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Immunology, 2026. Verfasst von Lu Ye und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Classical Chinese Medicine, The Third Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China. Hauptthemen laut MEDLINE: Kaempferols, Colorectal Neoplasms, Interleukin-17. Die Arbeit nennt 42 Literaturangaben. Gefördert von: He Ruoping National Traditional Chinese Medicine Expert Inheritance Studio Construction Project, Zhejiang Administration of Traditional Chinese Medicine Project, Seventh Batch of National Academic Experience Inheritance Program for Veteran Traditional Chinese Medicine Experts.
Abstract (Originalsprache)
Colorectal cancer (CRC) is a leading malignancy with limited treatment options at advanced stages. Interleukin (IL)-17 signaling promotes tumor progression and immune evasion. Kaempferol, a natural flavonol, has anti-inflammatory and antitumor effects, but its role in modulating IL-17 pathways in CRC is unclear. We used an immunocompetent MC38 xenograft model to evaluate kaempferol monotherapy (50/100 mg/kg), its combination with a PD-L1 inhibitor, and IL-17 overexpression. Tumor growth, immune infiltration, cytokines, and signaling pathways were assessed using immunohistochemistry, enzyme-linked immunosorbent assay, flow cytometry, and Western blotting. Kaempferol suppressed tumor growth in a dose-dependent manner and showed synergistic effects with PD-L1 inhibitors. It enhanced CD4+ and CD8+ T cell infiltration, reduced IL-17A+ γδ T cells, and increased IFN-γ+ γδ T cells. Kaempferol also downregulated IL-6, tumor necrosis factor α, and IL-17A and upregulated IL-2 and interferon γ. Molecular analyses showed inhibition of IL-17A, PD-L1, STAT3, and NF-κB pathway activation. IL-17A overexpression reversed these effects, restoring inflammation, immune suppression, and tumor growth. Kaempferol inhibits CRC progression by targeting IL-17–mediated inflammation and improving antitumor immunity, especially when combined with PD-L1 inhibitors. This study supports kaempferol’s potential as a novel therapeutic strategy for CRC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Classical Chinese Medicine, The Third Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China.
- Department of Geriatrics, The Third Affiliated Hospital of Zhejiang, Chinese Medical University, Hangzhou, China.
Förderung
- He Ruoping National Traditional Chinese Medicine Expert Inheritance Studio Construction Project
- Zhejiang Administration of Traditional Chinese Medicine Project
- Seventh Batch of National Academic Experience Inheritance Program for Veteran Traditional Chinese Medicine Experts
Zitieren
APA
Ye, L., Yu, M., & Liu, H. (2026). Kaempferol’s potential in targeting IL-17–mediated inflammatory pathways for colorectal cancer treatment. The Journal of Immunology. https://doi.org/10.1093/jimmun/vkag176
Vancouver
Ye L, Yu M, Liu H. Kaempferol’s potential in targeting IL-17–mediated inflammatory pathways for colorectal cancer treatment. The Journal of Immunology. 2026. doi:10.1093/jimmun/vkag176
BibTeX
@article{Ye2026,
author = {Ye, Lu and Yu, Mengjie and Liu, Huilin},
title = {Kaempferol’s potential in targeting IL-17–mediated inflammatory pathways for colorectal cancer treatment},
journal = {The Journal of Immunology},
year = {2026},
doi = {10.1093/jimmun/vkag176}
}
EUVIMED